SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Preventive Visit — Irène Joliot-Curie — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientIrène Joliot-Curie
Date of birth1897-09-12
IdentifiersMRN HR-RB003-SYN-TD; SSN (made up) 000-03-8841
Document date1955-10-26
AuthorSolène Marchand-Ellis, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Periodic adult preventive visit during treatment for acute myeloid leukemia. [S]

History of Present Illness

Mrs. Joliot-Curie is a 58-year-old physicist with acute myeloid leukemia, on day 29 of her first cycle of azacitidine with venetoclax, who comes for her yearly preventive visit, which she asked to keep. The nausea and constipation settled within a few days. She has had no fever. The day-22 marrow showed no leukemia under the microscope, and venetoclax is on hold while her counts recover. She is tired but walks a little every day and reads papers from her laboratory at home. She has met the palliative care team twice and the transplant center once. [S]

ElementDetail
VisitPeriodic adult preventive visit, age 58, during AML therapy
LeukemiaDay 29 of cycle 1; leukemia-free marrow on day 22; venetoclax on hold for count recovery
MoodPHQ-2 1; GAD-7 5

Health risk assessment. Completed by the patient on paper in the waiting room and reviewed with her by Dr. Marchand-Ellis. [S]

DomainFinding
Self-rated healthFair; better than a month ago
PsychosocialClose family and colleagues; worries about her laboratory and her students; no financial strain she wishes to discuss
Substance useAUDIT-C 1; no drug use
TobaccoNever uses tobacco
Physical activityShort walks daily
NutritionEating small frequent meals; follows food-safety advice for neutropenia
SleepSix to seven hours
SafetyWears a seat belt; no firearm at home; feels safe at home
OccupationalOff work in the laboratory during treatment; dose records requested from her employer
Activities of daily livingIndependent; needs rest after climbing stairs

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired; no fever, chills or night sweats
EyesNegativeNo change in vision
Ears, nose, mouth, and throatNegativeNo mouth sores; gum oozing has stopped
CardiovascularNegativeNo chest pain, palpitations or ankle swelling
RespiratoryPositiveBreathless on one flight of stairs, as before; no cough
GastrointestinalNegativeNausea gone; bowels regular
GenitourinaryNegativeNo urinary symptoms; periods ended in her early fifties
MusculoskeletalNegativeNo bone pain
IntegumentaryPositiveFading bruises on the shins
NeurologicalNegativeNo headache, numbness or confusion
Hematologic and lymphaticPositiveEasy bruising, improving
PsychiatricNegativeMood steady; PHQ-2 1, GAD-7 5

12 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Azacitidine 115 mg (75 mg/m2) under the skin once daily on days 1 to 7 of each 28-day cycleOnce daily on days 1 to 7 of each 28-day cycleSubcutaneous route1955-09-28activeS
Venetoclax 10 mg oral tablet, cycle 1: 10 mg on day 1 and 20 mg on day 2, then two tablets (20 mg) daily with the 50 mg tablet from day 4 (70 mg a day, reduced for posaconazole)Ramp-up, then two tablets daily with the 50 mg tablet, with food and waterOral route1955-09-28 to 1955-10-19completedS
Venetoclax 50 mg oral tablet, cycle 1: one tablet alone on day 3 (50 mg), then one tablet daily with two 10 mg tablets from day 4 (70 mg a day)One tablet daily from day 3, with food and waterOral route1955-09-28 to 1955-10-19completedS
Posaconazole 100 mg delayed-release tablet, three tablets (300 mg) twice on day 1, then three tablets once daily, as antifungal prophylaxis while neutropenic300 mg twice on day 1, then 300 mg once daily with foodOral route1955-09-28activeS
Acyclovir 400 mg oral tablet, one tablet twice daily as herpes simplex and zoster prophylaxisOne tablet twice dailyOral route1955-09-28activeS
Levofloxacin 500 mg oral tablet, one tablet daily while the neutrophil count is below 0.5One tablet daily during profound neutropeniaOral route1955-09-28 to 1955-10-30completedS
Allopurinol 300 mg oral tablet, one tablet daily for tumor lysis prophylaxis during cycle 1One tablet dailyOral route1955-09-28 to 1955-10-19completedS
Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nauseaOne tablet every 8 hours as neededOral route1955-10-08activeS
Polyethylene glycol 3350, 17 g powder in a glass of water once daily17 g once daily, held for loose stoolsOral route1955-10-08activeS
Sennosides 8.6 mg oral tablet, two tablets at bedtimeTwo tablets at bedtimeOral route1955-10-08 to 1955-10-19completedS
Potassium chloride 20 mEq extended-release tablet, one tablet twice daily for three daysOne tablet twice daily for three daysOral route1955-10-08 to 1955-10-11completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1955-10-26Body height163cmS
1955-10-26Body weight53.2kgS
1955-10-26Body mass index (BMI) [Ratio]20kg/m2S
1955-10-26Systolic blood pressure116mm[Hg]S
1955-10-26Diastolic blood pressure70mm[Hg]S
1955-10-26Heart rate86/minS
1955-10-26Respiratory rate16/minS
1955-10-26Body temperature36.8CelS
1955-10-26Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1955-10-26Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1955-10-26Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]5{score}S
1955-10-26Total score [AUDIT-C]1{score}S

Physical Exam

Vital signs recorded on 1955-10-26; see the Vital Signs section. [S]

SystemFinding
ConstitutionalTired but well; weight 53.2 kg, BMI 20.0; blood pressure 116/70
SkinFading bruises on the shins; no petechiae; no suspicious moles
MouthNo ulcers or thrush; teeth in good repair
NeckNo nodes; thyroid normal
CardiovascularRegular rhythm; no murmur; no ankle edema
RespiratoryFine crackles at the right apex, unchanged; otherwise clear
AbdomenSoft and non-tender; no enlarged liver or spleen
BreastsNo masses or skin change
PsychiatricComposed and engaged

Problems

ProblemClinical statusVerificationCodeProvenance
Two months of tiredness, easy bruising and bleeding gums, with pancytopenia and 12 percent blasts on the blood smear; acute leukemia suspected and urgent hematology review bookedresolvedconfirmed D61.818S — Synthetic presenting concern at the index visit, superseded by the bone marrow diagnosis two days later; its timing echoes the documented decline in her health (D).
Acute myeloid leukemia diagnosed on bone marrow biopsy (34 percent myeloblasts), in a physicist with decades of occupational exposure to ionizing radiation; synthetic modern diagnosis linked to her documented leukemiaactiveconfirmed C92.00S — Synthetic modern diagnosis and subtype; the type of her real leukemia is not documented.
Occupational exposure to ionizing radiation over about four decades: X-ray work early in her career, laboratory work with polonium and other radioactive sources, and a laboratory accident in which a sealed polonium source ruptured on her bench about ten years agoactiveconfirmed Z57.1S — Synthetic modern coding of her documented occupational exposure.
Pulmonary tuberculosis in her forties, treated to completion; no symptoms of active diseaseactiveconfirmed Z86.11S — Synthetic modern coding of her documented tuberculosis; the treatment details are synthetic.
Moderately reduced lung gas transfer (DLCO 58 percent of predicted, FEV1 76 percent) from old tuberculous scarring of the right upper lobe; with performance status 2, it makes her unfit for intensive inductionactiveconfirmed R94.2S — Synthetic finding on pre-treatment testing.
Nausea with vomiting and constipation on day 11 of cycle 1 of azacitidine with venetoclax, without fever, with mild low potassium; managed as an outpatient; resolvedresolvedconfirmed R11.2S — Synthetic treatment side effect; not a historical claim.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Blood pressure screeningCompleted today116/70 mmHg
Depression screeningCompleted todayPHQ-2 score 1
Anxiety screeningCompleted todayGAD-7 score 5, mild; supported by the palliative care team
Unhealthy alcohol use screeningCompleted todayAUDIT-C score 1
Tobacco useCompleted todayNever uses tobacco
HIV screeningUp to dateNegative before treatment
Hepatitis C screeningUp to dateNegative before treatment
Breast cancer screeningDueBiennial mammography is due; deferred during induction and revisited after treatment or before transplant
Cervical cancer screeningDueLast HPV test about four years ago, negative; due next year; deferred while counts are low
Colorectal cancer screeningDueColonoscopy about six years ago was normal; next due in four years; no test now while platelets are low
Lipid screening and statin assessmentDueDeferred during induction; to be discussed after treatment
Diabetes screeningNot indicatedNot overweight; glucose normal on her chemistry panels
Lung cancer screeningNot indicatedNever smoked
Osteoporosis screeningNot indicatedRoutine screening begins at 65; to be reconsidered before transplant because of the glucocorticoids and bone loss it can bring
Influenza vaccineCompleted todayInactivated vaccine; household contacts should also be vaccinated
COVID-19 vaccineOrderedThis season's vaccine ordered for the next infusion visit
Pneumococcal vaccineDueRecommended at 50 and over; deferred until at least three months after chemotherapy, or given on the transplant center's revaccination schedule, when it will work
Recombinant zoster vaccineDueRecommended at 50 and over; deferred until after treatment or as part of post-transplant revaccination; acyclovir prophylaxis in the meantime
Tetanus, diphtheria, and pertussisDueLast booster about eight years ago; next due in two years, after treatment
Hepatitis B vaccineDueNot immune on pre-treatment testing (all three markers negative); vaccinate after treatment or on the transplant schedule
Live vaccinesNot indicatedContraindicated during AML therapy
Dental examinationCompleted todayDental check before treatment found no infection; soft brush while platelets are low

Immunizations given today: Influenza vaccine, inactivated, this season [S]

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026); Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024 (PMID 38748941) (2024); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Age (2026)

Follow-up: Response review and cycle 2 decision in four days. COVID-19 vaccine at the next infusion visit. Deferred screening and vaccines to be revisited after treatment or before transplant. Next preventive visit in one year. Next scheduled visit 1955-10-30: count recovery and response assessment; cycle 2; transplant evaluation; occupational dose records. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 30 minutes, with her consent, building on her first meeting with the palliative care team. She understands that her leukemia is high risk and that a transplant offers the best chance of long remission but carries its own risks. She wants full treatment, including intensive care, while there is a reasonable chance of returning to a life she values, which for her means being able to think, read and talk about her work; she would not want prolonged life support if that were no longer possible. She named a health care agent, recorded in the confidential part of the chart and not named here, and completed an advance directive. To be revisited at each change in her illness. [S]